Abstract
The transforming growth factor-β (TGF-β) signaling pathway subserves an essential tumor suppressor function in various cell types. A heteromeric complex composed of TGF-β type I (RI) and type II (RII) receptors is required for TGF-β signaling. We have identified a subset of human gastric cancer cell lines which are insensitive to TGF-β and which express a low level of TGF-β type I receptor mRNA relative to a gastric cancer cell line which is highly responsive to TGF-β. Using these cells, we show that hypermethylation of a CpG island in the 5′ region of the TGF-β RI gene provides another potentially important mechanism of escape from negative growth control by TGF-β. This hypermethylation was found in four of five human gastric cancer cell lines and five out of 40 (12.5%) primary tumors examined. In human gastric cancer cell lines, treatment with the demethylating agent, 5-aza-2′-deoxycytidine, resulted in increased expression of the TGF-β RI gene, but not the RII gene. Transient transfection of an RI expression vector into the TGF-β resistant SNU-601 cell line restores TGF-β responsiveness. These findings suggest that one of the mechanisms of escape from autocrine or paracrine growth control by TGF-β during carcinogenesis could involve aberrant methylation of CpG islands in the 5′ region of the TGF-β RI gene.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- TGF-β:
-
transforming growth factor-β
- RII:
-
type II receptor
- RI:
-
type I receptor
- PCR:
-
polymerase chain reaction
References
Bird, AP. . 1986 Nature 321: 209–213.
Bloom BB, Humphries DE, Kuang P-P, Fine A and Goldstein RH. . 1996 Biochim. Biophysica Acta. 1312: 243–248.
Chang J, Park K, Bang Y-J, Kim WS, Kim D and Kim S-J. . 1997 Cancer Res. 57: 2856–2859.
Clark SJ, Harrison J, Paul CL and Frommer M. . 1994 Nucleic Acids Res. 22: 2990–2997.
Courey AJ and Tjian R. . 1988 Cell 55: 887–898.
Eshleman J and Markowitz S. . 1995 Curr. Opin. Oncol. 7: 83–89.
Franzén P, ten Dijke P, Ichijo H, Yamashita H, Schulz P, Heldin, C-H and Miyazono, K. . 1993 Cell 75: 681–692.
Garrigue-Antar L, Muñoz-Antonia T, Gesmonde J, Vellucci VF, and Reiss M. . 1995 Cancer Res. 55: 3892–3987.
Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM and Jones PA. . 1995 Cancer Res. 55: 4531–4535.
Greenberg M. . 1987 In: Ausubel, FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA and Struhl K . (eds). Current Protocols in Molecular Biology. John Wiley & Sons, Inc.: New York. pp. 4.10.1–4.10.7.
Herman, JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan D-S, Gnarra JR, Linehan WM and Baylin SB. . 1994 Proc. Natl. Acad. Sci. USA 91: 9700–9704.
Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB. . 1996 Proc. Natl. Acad. Sci. USA 93: 9821–9826.
Inagaki M, Moustaka A, Lin HY, Lodish HF and Carr BI. . 1993 Proc. Natl. Acad. Sci. USA 90: 5359–5363.
Issa J-P, Ottaviano YL, Celano P, Hamilton SR, Davidson NE and Baylin SB. . 1994 Nature Genet. 7: 536–540.
Jones PA. . 1996 Cancer Res. 56: 2463–2467.
Kadin M, Cavaille-Coll MW, Gertz R, Massagué J, Cheifetz S and George D. . 1994 Proc. Natl. Acad. Sci. USA 91: 6002–6006.
Kim DH and Kim S-J. . 1996 J. Biomed. Sci. 3: 143–158.
Kim Y, Ratziu V, Choi S-G, Lalazar A, Theiss G, Dang Q, Kim S-J and Friedman SL. . 1998 J. Biol. Chem. 273: 33750–33758.
Kimchi A, Wang X-F, Weinberg RA, Cheifetz S and Massagué J. . 1988 Science 240: 196–199.
Kolodner R. . 1996 Genes & Dev. 10: 1433–1442.
Lin H, Wang X-F, Ng-Eaton E, Weinberg R and Lodish H. . 1992 Cell 68: 775–785.
Markowitz SD, Wang J, Myeroff LL, Parsons R, Sun LZ, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, Brattain MG and Willson JKV. . 1995 Science 268: 1336–1338.
Markowitz SD and Roberts AB. . 1996 Cytokine and Growth Factor Reviews 7: 93–102.
Massagué, J. . 1990 Annu. Rev. Cell Biol. 6: 597–641.
Massagué J, Attisano L and Wrana J. . 1994 Trends Cell Biol. 4: 172–178.
Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB and Sidransky D. . 1995 Nature Med. 1: 686–692.
Miller IJ and Bieker JJ. . 1993 Mol. Cell. Biol. 13: 2776–2786.
Modrich P and Lahue R. . 1996 Annu. Rev. Biochem. 65: 101–133.
Myeroff LL, Parsons R, Kim S-J, Hedrick L, Cho KR, Orth K, Mathis M, Kinzler KW, Lutterbaugh J, Park K, Bang Y-J, Lee HY, Park J-G, Lynch HT, Roberts AB, Vogelstein B, Markowitz SD. . 1995 Cancer Res. 55: 5545–5547.
Park K, Kim S-J, Bang Y-J, Park J-G, Kim NK, Roberts AB and Sporn MB. . 1994 Proc. Natl. Acad. Sci. USA 9: 8772–8776.
Parsons R, Myeroff LL, Liu BL, Willson JKV, Markowitz SD, Kinzler KW and Vogelstein B. . 1995 Cancer Res. 55: 5548–5550.
Reiss M. . 1997 Oncology Res. 9: 447–457.
Rideout III WM, Eversole-Cire P, Spruck III CH, Hustad CM, Coetzee GA, Gonzales FA and Jones PA. . 1994 Mol. Cell. Biol. 14: 6143–6152.
Roberts AB and Sporn MB. . 1990 In: Robert AB and Sporn MB (eds). Peptide Growth Factors and Their Receptors. Handbook of Experimental Pharmacology. Springer-Verlag: Heidelburg. pp. 419–472.
Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM and Dryja TP. . 1991 Am. J. Human. Genet. 48: 880–888.
Suardet L, Gaide A-C, Calmes J-M, Sordat B, Givel J-C, Eliason JF and Odartchenko N. . 1992 Cancer Res. 52: 3705–3712.
Sun, L, Wu G, Willson JKV, Zborowska E, Yang J, Rajkarunanayake I., Wang J, Gentry LE, Wang X-F and Brattain MG. . 1994 J. Biol. Chem. 269: 26449–26455.
Wakefield LM and Sporn MB. . 1991 In: Klein G. (ed.) Tumor Suppressor Genes. Marcel Dekker Inc: New York and Basel pp. 217–243.
Wang J, Sun L, Myeroff LL, Wang X, Gentry LE, Yang J, Liang J, Zborowska E, Markowitz S, Willson JKV and Brattain MG. . 1995 J. Biol. Chem. 270: 22044–22049.
Wang J, Han W, Zborowska E, Liang J, Wang X, Wilson JKV, Sun L and Brattain MG. . 1996 J. Biol. Chem. 271: 17366–17371.
Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T and Hirohashi S. . 1995 Proc. Natl. Acad. Sci. USA 92: 7416–7419.
Acknowledgements
We thank Dr Anita Roberts for helpful discussion and critical review of the manuscript and Mariko Kato for expert technical assistance. This work was supported in part by grants from Korea Science and Engineering Foundation (KOSEF) through the CRC, the HAN Project, and the Korean Ministry of Science and Technology (MOST 8-1-10).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kang, S., Bang, YJ., Im, YH. et al. Transcriptional repression of the transforming growth factor-β type I receptor gene by DNA methylation results in the development of TGF-β resistance in human gastric cancer. Oncogene 18, 7280–7286 (1999). https://doi.org/10.1038/sj.onc.1203146
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203146
Keywords
This article is cited by
-
Endogenous sulfur dioxide alleviates collagen remodeling via inhibiting TGF-β/Smad pathway in vascular smooth muscle cells
Scientific Reports (2016)
-
DNA methylation: old dog, new tricks?
Nature Structural & Molecular Biology (2014)
-
Aberrant DNA methylation of integrin α4 in human breast cancer
Tumor Biology (2014)
-
The roles of TGFβ in the tumour microenvironment
Nature Reviews Cancer (2013)
-
TGF-β – an excellent servant but a bad master
Journal of Translational Medicine (2012)